Vericel Valuation

Is VCEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VCEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VCEL ($48.08) is trading above our estimate of fair value ($11.81)

Significantly Below Fair Value: VCEL is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VCEL?

Other financial metrics that can be useful for relative valuation.

VCEL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.3x
Enterprise Value/EBITDA-264.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does VCEL's PS Ratio compare to its peers?

The above table shows the PS ratio for VCEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average35.4x
MRUS Merus
60.2x41.4%US$2.7b
MYGN Myriad Genetics
2.8x7.4%US$2.0b
IRWD Ironwood Pharmaceuticals
5.3x15.8%US$2.4b
NTLA Intellia Therapeutics
73.3x56.6%US$2.7b
VCEL Vericel
12.4x20.2%US$2.3b

Price-To-Sales vs Peers: VCEL is good value based on its Price-To-Sales Ratio (12.4x) compared to the peer average (35.4x).


Price to Earnings Ratio vs Industry

How does VCEL's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.5%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.5%
n/an/an/a
No more companies

Price-To-Sales vs Industry: VCEL is good value based on its Price-To-Sales Ratio (12.4x) compared to the US Biotechs industry average (15.1x).


Price to Sales Ratio vs Fair Ratio

What is VCEL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VCEL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.4x
Fair PS Ratio6.5x

PM vs Fair Ratio: VCEL is expensive based on its Price-To-Sales Ratio (12.4x) compared to the estimated Fair Price-To-Sales Ratio (6.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VCEL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$48.08
US$46.90
-2.5%
8.1%US$53.00US$42.40n/a6
Feb ’25US$43.65
US$46.23
+5.9%
6.3%US$51.00US$42.40n/a6
Jan ’25US$35.61
US$42.58
+19.6%
5.0%US$45.00US$39.00n/a6
Dec ’24US$35.62
US$42.58
+19.5%
5.0%US$45.00US$39.00n/a6
Nov ’24US$35.00
US$40.75
+16.4%
9.6%US$44.50US$33.00n/a6
Oct ’24US$33.52
US$41.70
+24.4%
5.7%US$44.50US$39.00n/a5
Sep ’24US$33.88
US$41.00
+21.0%
4.6%US$44.00US$39.00n/a5
Aug ’24US$35.12
US$40.75
+16.0%
5.3%US$42.00US$37.00n/a4
Jul ’24US$37.57
US$39.25
+4.5%
7.1%US$42.00US$36.00n/a4
Jun ’24US$32.66
US$39.25
+20.2%
7.1%US$42.00US$36.00n/a4
May ’24US$32.22
US$37.75
+17.2%
12.3%US$44.00US$31.00n/a4
Apr ’24US$29.32
US$37.75
+28.8%
12.3%US$44.00US$31.00n/a4
Mar ’24US$29.99
US$37.75
+25.9%
12.3%US$44.00US$31.00n/a4
Feb ’24US$28.37
US$35.27
+24.3%
16.6%US$44.00US$29.00US$43.654
Jan ’24US$26.34
US$34.00
+29.1%
21.4%US$45.00US$25.00US$35.614
Dec ’23US$23.05
US$33.25
+44.3%
24.8%US$45.00US$22.00US$35.624
Nov ’23US$27.37
US$43.00
+57.1%
16.9%US$53.00US$34.00US$35.005
Oct ’23US$23.20
US$43.75
+88.6%
18.2%US$53.00US$34.00US$33.524
Sep ’23US$24.56
US$45.60
+85.7%
17.6%US$53.00US$34.00US$33.885
Aug ’23US$31.45
US$44.60
+41.8%
20.5%US$53.00US$33.00US$35.125
Jul ’23US$25.82
US$47.40
+83.6%
13.5%US$53.00US$36.00US$37.575
Jun ’23US$26.32
US$47.00
+78.6%
12.6%US$53.00US$36.00US$32.666
May ’23US$28.50
US$49.27
+72.9%
9.5%US$55.60US$44.00US$32.226
Apr ’23US$39.45
US$48.43
+22.8%
11.8%US$55.60US$40.00US$29.326
Mar ’23US$40.66
US$48.43
+19.1%
11.8%US$55.60US$40.00US$29.996
Feb ’23US$35.70
US$51.55
+44.4%
13.6%US$61.75US$40.00US$28.375

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.